The DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.
Medical Treatment of Advanced Testicular Cancer
Abstract
CONTEXT: The medical treatment of advanced testicular germ cell tumors has changed over the past 30 years, with long-term survival now achieved in the majority of patients. Clinicians need to be familiar with the available treatment regimens for testicular cancer and their associated toxic effects. OBJECTIVE: To review the treatments used for advanced testicular germ cell tumors and their associated short-term and long-term complications. EVIDENCE ACQUISITION: A search was performed of all English-language literature (1966 to October 2007) within the MEDLINE database using the terms neoplasms, germ cell, or embryonal or testicular neoplasms restricted to humans, drug therapy, complications, and mortality. The Cochrane Register of Controlled Trials Databases (through October 2007) was also searched using the terms testicular cancer or germ cell tumors. Bibliographies were reviewed to extract other relevant articles. One hundred eighty-six articles were selected based on pertinence to advanced testicular cancer treatment, associated complications, and late relapses with an emphasis on randomized controlled trials. DATA SYNTHESIS: The treatment of advanced testicular germ cell tumors with cisplatin combination chemotherapy is based on risk stratification (good, intermediate, or poor prognosis) according to pretreatment clinical features of prognostic value. Clinical trials have demonstrated that approximately 90% of patients classified as having a good prognosis achieve a durable complete remission to either 4 cycles of etoposide and cisplatin or 3 cycles of cisplatin, etoposide, and bleomycin. Complete responses are achieved less frequently for patients with intermediate- and poor-risk germ cell tumors, in whom 4 cycles of bleomycin, etoposide, and cisplatin remains the standard of care. Second- and third-line programs, including high-dose chemotherapy, also have curative potential. Chronic toxicities associated with therapy include cardiovascular disease, infertility, and secondary malignancies. Late relapses may also occur. CONCLUSIONS: Clinical trials have led to evidence-based treatment recommendations for advanced testicular cancer based on risk stratification. Clinicians should be familiar with the potential complications of these therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men
Lakka, H.-M. (2002) · JAMA · doi:10.1001/jama.288.21.2709 · Cited by 5,033
O'Leary, D. H., Polak, J. F., Kronmal, R. A., Manolio, T. A., Burke, G. L., & Wolfson, S. K. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901073400103 · Cited by 4,685
Lorenz, M. W., Markus, H. S., Bots, M. L., Rosvall, M., & Sitzer, M. (2007) · Circulation · doi:10.1161/circulationaha.106.628875 · Cited by 2,977
Gerstein, H. C. (2001) · JAMA · doi:10.1001/jama.286.4.421 · Cited by 2,440
Malik, S., Wong, N. D., Franklin, S. S., Kamath, T. V., L’Italien, G. J., Pio, J. R., & Williams, G. R. (2004) · Circulation · doi:10.1161/01.cir.0000140677.20606.0e · Cited by 1,848
EINHORN, L. H., & DONOHUE, J. (1977) · Annals of Internal Medicine · doi:10.7326/0003-4819-87-3-293 · Cited by 1,545
Williams, S. D., Birch, R., Einhorn, L. H., Irwin, L., Greco, F. A., & Loehrer, P. J. (1987) · New England Journal of Medicine · doi:10.1056/nejm198706043162302 · Cited by 1,170
Cited by
Molecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760
Microbial drug discovery: 80 years of progress
Demain, A. L., & Sanchez, S. (2009) · The Journal of Antibiotics · doi:10.1038/ja.2008.16 · Cited by 1,002
Platinum-based drugs: past, present and future
Dilruba, S., & Kalayda, G. V. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-2976-z · Cited by 906
Systems biology of cisplatin resistance: past, present and future
Galluzzi, L., Vitale, I., Michels, J., Brenner, C., Szabadkai, G., Harel-Bellan, A., Castedo, M., & Kroemer, G. (2014) · Cell Death & Disease · doi:10.1038/cddis.2013.428 · Cited by 782
Cheng, L., Albers, P., Berney, D. M., Feldman, D. R., Daugaard, G., Gilligan, T., & Looijenga, L. H. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0029-0 · Cited by 462
Self-citation
Metadata
- Authors
- Feldman, D. R.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2008-02-13
- Volume
- 299
- Issue
- 6
- Pages
- 672
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2160492795
- Cited by
- 370
- References
- 107
- FWCI
- 24.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Medical Treatment of Advanced Testicular Cancer. https://app.cochat.ai/papers/10.1001/jama.299.6.672
- The paper
- Feldman, D. R. (2008). Medical Treatment of Advanced Testicular Cancer. JAMA. https://doi.org/10.1001/jama.299.6.672
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.